为了进一步提高KRAS G12C突变患者的治疗效果，研究团队设计了一项临床试验。他们尝试将靶向药索托拉西布与传统化疗（卡铂和培美曲塞）相结合，用于治疗晚期非鳞状非小细胞肺癌患者。

相关研究成果于 2025 年 1 月 22 日发表在了 Nature Biotechnology 期刊，论文题为：Quantum-computing-enhanced algorithm unveils potential KRAS inhibitors。 KRAS 突变是癌症 ...

This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma, continuing a move into ...

Groups partner on research project to test innovative new treatment for KRAS-mutant cancer being developed at Hebrew ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

Bristol-Myers Squibb’s KRAS inhibitor Krazati has been approved for a second indication, colorectal cancer (CRC), which could inject some much-needed sales growth into the product. The FDA has ...

近期，英矽智能与加拿大多伦多大学共同主导的一项研究首次展示量子计算和人工智能在变革药物发现流程方面的潜力。在这 ...

The findings revealed that tumors with higher levels of RAS–RAF protein interaction were more likely to respond to KRASG12C inhibitors ... for patients with KRAS-mutant cancers." ...

coupled with recent breakthroughs in targeting KRAS mutations such as the KRAS G12C inhibitors, made it a compelling starting point.” “The computational exploration of KRAS provided an ...

Phase II study of niraparib and dostarlimab for the treatment of germline or somatic homologous recombination repair mutated (HRD) metastatic pancreatic cancer.

“With the addition of VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, we are well-positioned to further establish our leadership in targeting RAS/MAPK pathway-driven ...